BLA 761065 · Theratechnologies
Trogarzo
Ibalizumab-Uiyk · Injection · CD4-directed Blocking Antibody; Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 12, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Mar 6, 2018
Approved uses
2
Original approval plus efficacy supplements
Registered trials
13
4 Phase 3, 1 recruiting
FAERS reports
540
220 serious, 38 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 7, 2026.
TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen. TROGARZO, a CD4-directed post-attachment HIV-1 inhibitor, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.
Mechanism: Ibalizumab-uiyk is an HIV-1 antiretroviral drug [see Microbiology ( 12.4 )] .
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 3, 2022 Supplement 13 · Efficacy OrphanLabel
- Mar 6, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- TROGARZO · IBALIZUMAB-UIYK 150MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ibalizumab" as an intervention, any sponsor and status, largest first.
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05502341 · 689 participants · Start Aug 16, 2022 · Primary completion Sep 29, 2025
Drug: Bictegravir; Lenacapavir and 2 more · For: HIV-1-infection
Sites: Berkeley, California; Beverly Hills, California; Los Angeles, California · 94 sites in all
- Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1Pivotal-lookingCompleted
TaiMed Biologics Inc.Industry
NCT00784147 · 113 participants · Start Aug 2008 · Primary completion Apr 2011
Drug: Ibalizumab; Ibalizumab · For: HIV
Sites: Beverly Hills, California; Long Beach, California; Los Angeles, California · 30 sites in all
- TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1Status unknown
TanoxIndustry
NCT00089700 · 80 participants · Start Mar 2004
Drug: TNX-355 · For: HIV Infections
Sites: Phoenix, Arizona; Los Angeles, California; Washington D.C., District of Columbia · 15 sites in all
- Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1Pivotal-lookingCompleted
TaiMed Biologics Inc.Industry
NCT02707861 · 79 participants · Start Mar 2016 · Primary completion Nov 2018
Drug: ibalizumab; Optimized Background Regimen · For: HIV
Sites: Long Beach, California; Los Angeles, California; Palm Springs, California · 32 sites in all
- Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular InjectionPivotal-lookingCompleted
TaiMed Biologics Inc.Industry
NCT03913195 · 43 participants · Start May 30, 2019 · Primary completion Oct 17, 2022
Drug: ibalizumab-uiyk · For: HIV-1-infection
Sites: Los Angeles, California; Fort Lauderdale, Florida; Orlando, Florida · 4 sites in all
- Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIVPivotal-lookingCompleted
TaiMed Biologics Inc.Industry
NCT02475629 · 40 participants · Start Aug 2015 · Primary completion Oct 2016
Drug: ibalizumab; Optimized Background Regimen (OBR) · For: HIV
Sites: Long Beach, California; Los Angeles, California; Palm Springs, California · 30 sites in all
Huda SalmanAcademic, hospital or other
NCT06197672 · 30 participants (planned) · Start Mar 19, 2024 · Primary completion Dec 2027
Drug: CD4CAR · For: Acute Myeloid Leukemia
Sites: Miami, Florida; Indianapolis, Indiana; Houston, Texas · 4 sites in all
Huda SalmanAcademic, hospital or other
NCT06071624 · 30 participants (planned) · Start Feb 21, 2024 · Primary completion Dec 2028
Drug: CD4CAR · For: Chronic Myelomonocytic Leukemia
Sites: Miami, Florida; Indianapolis, Indiana; The Bronx, New York · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product dose omission issue45
- viral load increased45
- drug ineffective44
- rash43
- hospitalisation36
- fatigue30
- off label use30
- diarrhoea28
- nausea26
- death25
- pruritus25
- dizziness21
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 45 |
| 2019 | 41 |
| 2020 | 73 |
| 2021 | 69 |
| 2022 | 86 |
| 2023 | 82 |
| 2024 | 66 |
| 2025 | 53 |
| 2026 | 23 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Trogarzo (Ibalizumab-Uiyk)
2024 spending
$12.4M
Beneficiaries
107
1,213 claims
Per beneficiary
$115,873
$1,096.33 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $14,136,158 |
| 2021 | $12,698,850 |
| 2022 | $12,880,976 |
| 2023 | $14,106,188 |
| 2024 | $12,398,416 |
Part B: Trogarzo (Ibalizumab-Uiyk) · HCPCS J1746
2024 spending
$1.6M
Beneficiaries
19
235 claims
Per beneficiary
$82,264
2024 ASP limit $75.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,608,887 |
| 2021 | $1,556,156 |
| 2022 | $1,681,553 |
| 2023 | $1,631,358 |
| 2024 | $1,563,019 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
Emu B, Fessel J, Schrader S, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Comparative Efficacy and Safety of Fostemsavir in Heavily Treatment-Experienced People With HIV-1.
Anderson SJ, van Doornewaard A, Turner M, et al. · Clin Ther 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Efficacy and Safety of 2 Fixed Doses of Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced HIV-Positive Individuals.
DeJesus E, Towner WJ, Gathe JC, et al. · J Acquir Immune Defic Syndr 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
- Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus.
Chatzidaki I, Curteis T, Luedke H, et al. · Value Health 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study.
Gathe JC, Hardwicke RL, Garcia F, et al. · J Acquir Immune Defic Syndr 2021 · Clinical Trial, Phase II, Randomized Controlled Trial
- Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review.
Toledo T, Castro T, Oliveira VG, et al. · Clin Pharmacokinet 2023 · Systematic Review
Sponsor: Theratechnologies
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.